Skip to main content
Top
Published in: Clinical and Experimental Nephrology 5/2014

01-10-2014 | Original Article

Retrospective analysis of factors predicting end-stage renal failure or death in patients with microscopic polyangiitis with mainly renal involvement

Authors: Hirohisa Kawai, Shogo Banno, Shogo Kikuchi, Nahoko Nishimura, Hironobu Nobata, Yukihiro Kimura, Yumiko Takezawa, Mari Ogawa, Keisuke Suzuki, Wataru Kitagawa, Naoto Miura, Hirokazu Imai

Published in: Clinical and Experimental Nephrology | Issue 5/2014

Login to get access

Abstract

Background

The aim of this study was to identify risk factors for end-stage renal failure (ESRF) or death in Japanese patients with microscopic polyangiitis (MPA) with renal involvement.

Methods

From 54 consecutive patients with systemic vasculitis based on Watt’s algorithm, we retrospectively analyzed 39 MPA patients with renal involvement, including 19 (48.7 %) with renal-limited vasculitis.

Results

Thirty-three of 39 patients (84.6 %) demonstrated rapidly progressive glomerulonephritis, and 13 (33.3 %) developed ESRF; 8 of 13 required dialysis within 1 week. Thirteen (33.3 %) died during follow-up of more than 12 months, and 7 died during the first 6 months, mainly because of opportunistic infections. Overall survival at 6 and 12 months was 79.5 and 71.1 %, respectively. Serum creatinine levels did not differ significantly between survivors and non-survivors (P = 0.092). The mean Birmingham Vasculitis Activity Score, version 3 (BVAS v.3), was 16.2 ± 6.5, with a renal subscore of over 12 points in 82.1 %, and BVAS v.3 was marginally higher in non-survivors than survivors (P = 0.045). An age- and sex-adjusted Cox proportional hazards analysis demonstrated that neither the serum creatinine level (P = 0.277) nor BVAS v.3 (P = 0.188) at initial diagnosis was a risk factor for overall survival. The baseline serum creatinine cutoff value for discriminating between ESRF and non-ESRF was 4.6 mg/dl, with a sensitivity and specificity of 92.3 and 84.6 %, respectively.

Conclusions

Survival rates do not relate to ESRF in MPA patients with mainly renal involvement. Although patients with ESRF required regular hemodialysis, longer survival can be achieved.
Literature
1.
go back to reference Lionaki S, Blyth ER, Hogan SL, Hu Y, Senior BA, Jennette CE, et al. Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthr Rheum. 2012;64:3452–62.CrossRef Lionaki S, Blyth ER, Hogan SL, Hu Y, Senior BA, Jennette CE, et al. Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthr Rheum. 2012;64:3452–62.CrossRef
2.
go back to reference Watts RA, Scott DG, Jayne DR, Ito-Ihara T, Muso E, Fujimoto S, et al. Renal vasculitis in Japan and the UK—are there differences in epidemiology and clinical phenotype? Nephrol Dial Transplant. 2008;23:3928–31.PubMedCrossRef Watts RA, Scott DG, Jayne DR, Ito-Ihara T, Muso E, Fujimoto S, et al. Renal vasculitis in Japan and the UK—are there differences in epidemiology and clinical phenotype? Nephrol Dial Transplant. 2008;23:3928–31.PubMedCrossRef
3.
go back to reference Fujimoto S, Watts RA, Kobayashi S, Suzuki K, Jayne DR, Scott DG, et al. Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis between Japan and the UK. Rheumatology. 2011;50:1916–20.PubMedCrossRef Fujimoto S, Watts RA, Kobayashi S, Suzuki K, Jayne DR, Scott DG, et al. Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis between Japan and the UK. Rheumatology. 2011;50:1916–20.PubMedCrossRef
4.
go back to reference Suzuki Y, Takeda Y, Sato D, Kanaguchi Y, Tanaka Y, Kobayashi S, et al. Clinicoepidemiological manifestations of RPGN and ANCA-associated vasculitides: an 11-year retrospective hospital-based study in Japan. Mod Rheumatol. 2010;20:54–62.PubMedCrossRef Suzuki Y, Takeda Y, Sato D, Kanaguchi Y, Tanaka Y, Kobayashi S, et al. Clinicoepidemiological manifestations of RPGN and ANCA-associated vasculitides: an 11-year retrospective hospital-based study in Japan. Mod Rheumatol. 2010;20:54–62.PubMedCrossRef
5.
go back to reference Yamagata K, Usui J, Saito C, Yamaguchi N, Hirayama K, Mase K, et al. ANCA-associated systemic vasculitis in Japan: clinical features and prognostic changes. Clin Exp Nephrol. 2012;16:580–8.PubMedCrossRef Yamagata K, Usui J, Saito C, Yamaguchi N, Hirayama K, Mase K, et al. ANCA-associated systemic vasculitis in Japan: clinical features and prognostic changes. Clin Exp Nephrol. 2012;16:580–8.PubMedCrossRef
6.
go back to reference Bourgarit A, Le Toumelin P, Pagnoux C, Cohen P, Mahr A, Le Guern V, et al. Deaths occurring during the first year after treatment onset for polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: a retrospective analysis of causes and factors predictive of mortality based on 595 patients. Medicine. 2005;84:323–30.PubMedCrossRef Bourgarit A, Le Toumelin P, Pagnoux C, Cohen P, Mahr A, Le Guern V, et al. Deaths occurring during the first year after treatment onset for polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: a retrospective analysis of causes and factors predictive of mortality based on 595 patients. Medicine. 2005;84:323–30.PubMedCrossRef
7.
go back to reference Corral-Gudino L, Borao-Cengotita-Bengoa M, Del Pino-Montes J, Lerma-Márquez JL. Overall survival, renal survival and relapse in patients with microscopic polyangiitis: a systematic review of current evidence. Rheumatology. 2011;50:1414–23.PubMedCrossRef Corral-Gudino L, Borao-Cengotita-Bengoa M, Del Pino-Montes J, Lerma-Márquez JL. Overall survival, renal survival and relapse in patients with microscopic polyangiitis: a systematic review of current evidence. Rheumatology. 2011;50:1414–23.PubMedCrossRef
8.
go back to reference Luqmani RA, Exley AR, Kitas GD, Bacon PA. Disease assessment and management of the vasculitides. Baillieres Clin Rheumatol. 1997;11:423–46.PubMedCrossRef Luqmani RA, Exley AR, Kitas GD, Bacon PA. Disease assessment and management of the vasculitides. Baillieres Clin Rheumatol. 1997;11:423–46.PubMedCrossRef
9.
go back to reference Mukhtyar C, Lee R, Brown D, Carruthers D, Dasgupta B, Dubey S, et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis. 2009;68:1827–32.PubMedCrossRef Mukhtyar C, Lee R, Brown D, Carruthers D, Dasgupta B, Dubey S, et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis. 2009;68:1827–32.PubMedCrossRef
10.
go back to reference Berden AE, Ferrario F, Hagen EC, Jayne DR, Jennette JC, Joh K, et al. Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol. 2010;21:1628–36.PubMedCrossRef Berden AE, Ferrario F, Hagen EC, Jayne DR, Jennette JC, Joh K, et al. Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol. 2010;21:1628–36.PubMedCrossRef
11.
go back to reference Sugiyama K, Sada KE, Kurosawa M, Wada J, Makino H. Current status of the treatment of microscopic polyangiitis and granulomatosis with polyangiitis in Japan. Clin Exp Nephrol. 2013;17:51–8.PubMedCrossRefPubMedCentral Sugiyama K, Sada KE, Kurosawa M, Wada J, Makino H. Current status of the treatment of microscopic polyangiitis and granulomatosis with polyangiitis in Japan. Clin Exp Nephrol. 2013;17:51–8.PubMedCrossRefPubMedCentral
12.
go back to reference Weidner S, Geuss S, Hafezi-Rachti S, Wonka A, Rupprecht HD. ANCA-associated vasculitis with renal involvement: an outcome analysis. Nephrol Dial Transplant. 2004;19:1403–11.PubMedCrossRef Weidner S, Geuss S, Hafezi-Rachti S, Wonka A, Rupprecht HD. ANCA-associated vasculitis with renal involvement: an outcome analysis. Nephrol Dial Transplant. 2004;19:1403–11.PubMedCrossRef
13.
go back to reference Uezono S, Sato Y, Hara S, Hisanaga S, Fukudome K, Fujimoto S, et al. Outcome of ANCA-associated primary renal vasculitis in Miyazaki Prefecture. Intern Med. 2007;46:815–22.PubMedCrossRef Uezono S, Sato Y, Hara S, Hisanaga S, Fukudome K, Fujimoto S, et al. Outcome of ANCA-associated primary renal vasculitis in Miyazaki Prefecture. Intern Med. 2007;46:815–22.PubMedCrossRef
14.
go back to reference Watanabe K, Tani Y, Kimura H, Tanaka K, Hayashi Y, Asahi K, et al. Clinical outcomes of Japanese MPO-ANCA-related nephritis: significance of initial renal death for survival. Intern Med. 2012;51:1969–76.PubMedCrossRef Watanabe K, Tani Y, Kimura H, Tanaka K, Hayashi Y, Asahi K, et al. Clinical outcomes of Japanese MPO-ANCA-related nephritis: significance of initial renal death for survival. Intern Med. 2012;51:1969–76.PubMedCrossRef
15.
go back to reference Itabashi M, Takei T, Yabuki Y, Suzuki H, Ando M, Akamatsu M, et al. Clinical outcome and prognosis of anti-neutrophil cytoplasmic antibody-associated vasculitis in Japan. Nephron Clin Pract. 2010;115:c21–7.PubMedCrossRef Itabashi M, Takei T, Yabuki Y, Suzuki H, Ando M, Akamatsu M, et al. Clinical outcome and prognosis of anti-neutrophil cytoplasmic antibody-associated vasculitis in Japan. Nephron Clin Pract. 2010;115:c21–7.PubMedCrossRef
16.
go back to reference Flossmann O, Berden A, de Groot K, Hagen C, Harper L, Heijl C, et al. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis. 2011;70:488–94.PubMedCrossRef Flossmann O, Berden A, de Groot K, Hagen C, Harper L, Heijl C, et al. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis. 2011;70:488–94.PubMedCrossRef
17.
go back to reference Ahn JK, Hwang JW, Lee J, Jeon CH, Cha HS, Koh EM. Clinical features and outcome of microscopic polyangiitis under a new consensus algorithm of ANCA-associated vasculitides in Korea. Rheumatol Int. 2012;32:2979–86.PubMedCrossRef Ahn JK, Hwang JW, Lee J, Jeon CH, Cha HS, Koh EM. Clinical features and outcome of microscopic polyangiitis under a new consensus algorithm of ANCA-associated vasculitides in Korea. Rheumatol Int. 2012;32:2979–86.PubMedCrossRef
18.
go back to reference Itabashi M, Takei T, Morito T, Yabuki Y, Suzuki H, Ando M, et al. Estimation of BVAS in patients with microscopic polyangiitis in Japan. Clin Rheumatol. 2011;30:1499–505.PubMedCrossRef Itabashi M, Takei T, Morito T, Yabuki Y, Suzuki H, Ando M, et al. Estimation of BVAS in patients with microscopic polyangiitis in Japan. Clin Rheumatol. 2011;30:1499–505.PubMedCrossRef
19.
go back to reference Koike K, Fukami K, Yonemoto K, Iwatani R, Obata R, Ueda K, et al. A new vasculitis activity score for predicting death in myeloperoxidase-antineutrophil cytoplasmic antibody-associated vasculitis patients. Am J Nephrol. 2012;35:1–6.PubMedCrossRef Koike K, Fukami K, Yonemoto K, Iwatani R, Obata R, Ueda K, et al. A new vasculitis activity score for predicting death in myeloperoxidase-antineutrophil cytoplasmic antibody-associated vasculitis patients. Am J Nephrol. 2012;35:1–6.PubMedCrossRef
20.
go back to reference Bomback AS, Appel GB, Radhakrishnan J, Shirazian S, Herlitz LC, Stokes B, et al. ANCA-associated glomerulonephritis in the very elderly. Kidney Int. 2011;79:757–64.PubMedCrossRef Bomback AS, Appel GB, Radhakrishnan J, Shirazian S, Herlitz LC, Stokes B, et al. ANCA-associated glomerulonephritis in the very elderly. Kidney Int. 2011;79:757–64.PubMedCrossRef
21.
go back to reference Booth AD, Almond MK, Burns A, Ellis P, Gaskin G, Neild GH, et al. Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis. 2003;41:776–84.PubMedCrossRef Booth AD, Almond MK, Burns A, Ellis P, Gaskin G, Neild GH, et al. Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis. 2003;41:776–84.PubMedCrossRef
22.
go back to reference Chen YX, Yu HJ, Zhang W, Ren H, Chen XN, Shen PY, et al. Analyzing fatal cases of Chinese patients with primary antineutrophil cytoplasmic antibodies-associated renal vasculitis: a 10-year retrospective study. Kidney Blood Press Res. 2008;31:343–9.PubMedCrossRef Chen YX, Yu HJ, Zhang W, Ren H, Chen XN, Shen PY, et al. Analyzing fatal cases of Chinese patients with primary antineutrophil cytoplasmic antibodies-associated renal vasculitis: a 10-year retrospective study. Kidney Blood Press Res. 2008;31:343–9.PubMedCrossRef
23.
go back to reference Koyama A, Yamagata K, Makino H, Arimura Y, Wada T, Nitta K, et al. A nationwide survey of rapidly progressive glomerulonephritis in Japan: etiology, prognosis and treatment diversity. Clin Exp Nephrol. 2009;13:633–50.PubMedCrossRef Koyama A, Yamagata K, Makino H, Arimura Y, Wada T, Nitta K, et al. A nationwide survey of rapidly progressive glomerulonephritis in Japan: etiology, prognosis and treatment diversity. Clin Exp Nephrol. 2009;13:633–50.PubMedCrossRef
24.
go back to reference Hogan SL, Nachman PH, Wilkman AS, Jennette JC, Falk RJ. Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol. 1996;7:23–32.PubMed Hogan SL, Nachman PH, Wilkman AS, Jennette JC, Falk RJ. Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol. 1996;7:23–32.PubMed
25.
go back to reference Wada T, Hara A, Arimura Y, Sada KE, Makino H. Risk factors associated with relapse in Japanese patients with microscopic polyangiitis. J Rheumatol. 2012;39:545–51.PubMedCrossRef Wada T, Hara A, Arimura Y, Sada KE, Makino H. Risk factors associated with relapse in Japanese patients with microscopic polyangiitis. J Rheumatol. 2012;39:545–51.PubMedCrossRef
26.
go back to reference Jayne DR, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L, et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for sever renal vasculitis. J Am Soc Neohrol. 2007;18:2180–8.CrossRef Jayne DR, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L, et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for sever renal vasculitis. J Am Soc Neohrol. 2007;18:2180–8.CrossRef
27.
go back to reference de Lind van Wijngaarden RA, Hauer HA, Wolterbeek R, Jayne DR, Gaskin G, Rasmussen N, Noel LH, et al. Chances of renal recovery for dialysis-dependent ANCA-associated glomerulonephritis. J Am Soc Nephrol. 2007;18:2189–97.PubMedCrossRef de Lind van Wijngaarden RA, Hauer HA, Wolterbeek R, Jayne DR, Gaskin G, Rasmussen N, Noel LH, et al. Chances of renal recovery for dialysis-dependent ANCA-associated glomerulonephritis. J Am Soc Nephrol. 2007;18:2189–97.PubMedCrossRef
28.
go back to reference Joh K, Muso E, Shigematsu H, Nose M, Nagata M, Arimura Y, et al. Renal pathology of ANCA-related vasculitis: proposal for standardization of pathological diagnosis in Japan. Clin Exp Nephrol. 2008;12:277–91.PubMedCrossRef Joh K, Muso E, Shigematsu H, Nose M, Nagata M, Arimura Y, et al. Renal pathology of ANCA-related vasculitis: proposal for standardization of pathological diagnosis in Japan. Clin Exp Nephrol. 2008;12:277–91.PubMedCrossRef
29.
go back to reference Ferrario F, Vanzati A, Pagni F. Pathology of ANCA-associated vasculitis. Clin Exp Nephrol. 2013;17:652–8.PubMedCrossRef Ferrario F, Vanzati A, Pagni F. Pathology of ANCA-associated vasculitis. Clin Exp Nephrol. 2013;17:652–8.PubMedCrossRef
Metadata
Title
Retrospective analysis of factors predicting end-stage renal failure or death in patients with microscopic polyangiitis with mainly renal involvement
Authors
Hirohisa Kawai
Shogo Banno
Shogo Kikuchi
Nahoko Nishimura
Hironobu Nobata
Yukihiro Kimura
Yumiko Takezawa
Mari Ogawa
Keisuke Suzuki
Wataru Kitagawa
Naoto Miura
Hirokazu Imai
Publication date
01-10-2014
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 5/2014
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-013-0926-1

Other articles of this Issue 5/2014

Clinical and Experimental Nephrology 5/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.